Eurocopter France: Tail Rotor Blades

Patwardhan B: Ethnopharmacology and drug discovery. J Ethnopharmacol 2005;100:50-52. Pina AS, Hussain A, Roque AC: An historical overview of drug discovery. Methods Mol Biol 2009;572:3-12. Warren JV: William Withering revisited: 200 years of the ...

National Storage Mechanism Appointed by the FCA to act as the official mechanism for the storage of regulated information in the UK RNS Number : 3150F Local Shopping REIT (The) PLC 22 May 2013 ? TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1.

Indian markets turned negative towards closing led by Larsen & Toubro. At 2.11 pm, the Sensex was trading down 27.85 points or 0.14% at 20,083.76 with 15 components falling. Meanwhile, the Nifty was trading lower by 6.10 points or 0.10% at 6,108 ...

Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today, further to the Company's announcement dated May 9, 2013 that it had filed a motion with the Tel Aviv District Court (the "Court") to convene meetings of its unsecured ...

PIMCO US Dollar Short Maturity Source ETF (the "Sub-Fund") iNAV per share: 101.006261 as of 16:30 GMT on 21 May Number of outstanding shares: 12,240,619 Portfolio Disclosure SWEDISH EXPORT CREDIT SWEDISH EXPORT CREDIT FRN SR UNSEC EMTN ALTRIA GROUP ...

National Storage Mechanism Appointed by the FCA to act as the official mechanism for the storage of regulated information in the UK RNS Number : 2575F Epoch Investment Partners, Inc. 21 May 2013 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING ...

VEHICLE MONITORING SYSTEMS PTY LIMITED ACN 107 396 136 v SARB MANAGEMENT GROUP PTY LTD (T/A DATABASE CONSULTANTS AUSTRALIA) ACN 106 549 722 File number: YATES J Date of judgment: 3 May 2013 PATENTS innovation patent methods and apparatuses for ...

The lack of adequate pedestrian behavior models means that designing for walkability has largely remained a matter of intuition. However, agent-based simulation can provide insight into the keys for creating pedestrian-friendly places. La Citta Vita ...

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof.